Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H077 vs Silodosin in Benign Prostatic Hyperplasia
NCT07146386Phase 3Not yet recruiting
- Sponsor
- Shanghai Huilun Pharmaceutical Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of silodosin in benign prostatic hyperplasia (BPH), sponsored by Shanghai Huilun Pharmaceutical Co., Ltd.. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
silodosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT07146386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07146386.